Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Bladder Cancer
Recurrent bladder cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the bladder or in other parts of the body. ...
Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Bladder Cancer
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. The bladder is a hollow organ in the lower part of the abdomen. It is shaped like a small balloon and has a muscular wall that allows it to get larger or smaller. The bladder stores urine until it is passed out of the body. Urine is the liquid waste that is made by the kidneys when they clean the
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Bladder Cancer
Note: Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more information.) Stage I bladder cancer is defined by the following TNM classification: T1,N0,...
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (02 / 08 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. General Information About Bladder CancerUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
PURPOSE OF THIS SUMMARY This PDQ cancer information summary for health professionals provides comprehensive,peer-reviewed,evidence-based information about the treatment of bladder cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. REVIEWERS AND UPDATES ...
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Proximal Urethral Cancer
Female Proximal Urethral CancerLesions of the proximal or entire length of the urethra are usually associated with invasion and a high incidence of pelvic nodal metastases. The prospects for cure are limited except in the case of small tumors. The best results have been achieved with exenterative surgery and urinary diversion with 5-year survival rates ranging from 10% to 20%. To increase the resectability rate of gross tumor and decrease local recurrence, in an effort to shrink tumor margins, it is reasonable to recommend adjunctive, preoperative, radiation therapy. Pelvic lymphadenectomy is performed concomitantly. Ipsilateral inguinal node dissection is indicated only if biopsy specimens of ipsilateral palpable adenopathy are positive on frozen section. For tumors that do not exceed 2 cm in greatest dimension, radiation alone, nonexenterative surgery alone, or a combination of the two may be sufficient to provide an excellent outcome.It is reasonable to consider removal of part of
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage 0 Bladder Cancer
Stage 0 bladder cancer is defined by the following TNM classifications:Ta, N0, M0Tis, N0, M0Patients with stage 0 bladder tumors can be cured by a variety of treatments, even though the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors, who were followed for a minimum of 20 years or until death, the risk of bladder cancer recurrence following initial resection was 80%. Patients at greatest risk of recurrent disease are those whose tumors are large, poorly differentiated, multiple, or associated with nuclear p53 overexpression. In addition, patients with carcinoma in situ (Tis) or dysplasia of grossly uninvolved bladder epithelium are at greater risk of recurrence and progression.[1,2,3]Transurethral resection (TUR) and fulguration are the most common and conservative forms of management. Careful surveillance of subsequent bladder tumor progression is important. One retrospective series addressed the value of performing a second TUR
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Get more information on urethral cancer treatment. How to contact the National Cancer Institute (NCI) via phone (1-800-4-Cancer), online, or mail. Plus, details on how to search the NCI web site, and how to order NCI publications.
Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Bladder Cancer
Treatment of recurrent bladder cancer depends on previous treatment and where the cancer has recurred. Treatment for recurrent bladder cancer may include the following: Surgery. Chemotherapy. Radiation therapy. A clinical trial of chemotherapy. This summary section refers to specific treatments under study in clinical trials,but it may not mention every new treatment being studied. ...
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent or Metastatic Urethral Cancer
Local recurrences of urethral cancer may be amenable to local modality therapy with radiation or surgery, with or without chemotherapy. (Refer to the Treatment Option Overview section of this summary for more information.) Metastatic disease may be treated with regimens in common use for other urothelial transitional cell or squamous cell carcinomas, or anal carcinomas, depending upon the histology.[1,2,3]Treatment options:Locally recurrent urethral cancer after radiation therapy should be treated by surgical excision, if feasible.Locally recurrent urethral cancer after surgery alone should be considered for combination radiation and wider surgical resection.Metastatic urethral cancer should be considered for clinical trials using chemotherapy. Transitional cell cancer of the urethra may respond favorably to the same chemotherapy regimens employed for advanced transitional cell cancer of the bladder.[2,3,4,5]The level of evidence for these treatment options is 3iiiDiv.Current Clinical